|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BIM 26182 and BIM 26189 injected at the doses of 50 micrograms twice a day (s.c.) around the tumor for 10 to 21 days delayed the growth of SCLC 41 and of SCLC 75.
|
1325285 |
1992 |
|
Small cell carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
BIM 26182 and BIM 26189 injected at the doses of 50 micrograms twice a day (s.c.) around the tumor for 10 to 21 days delayed the growth of SCLC 41 and of SCLC 75.
|
1325285 |
1992 |
|
Neuroblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have previously found that in the human neuroblastoma cell line SY5Y the SST analogue lanreotide (BIM 23014) inhibited serum-stimulated cell proliferation and MAP kinase activity.
|
10508918 |
1999 |
|
Central neuroblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have previously found that in the human neuroblastoma cell line SY5Y the SST analogue lanreotide (BIM 23014) inhibited serum-stimulated cell proliferation and MAP kinase activity.
|
10508918 |
1999 |
|
Childhood Neuroblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have previously found that in the human neuroblastoma cell line SY5Y the SST analogue lanreotide (BIM 23014) inhibited serum-stimulated cell proliferation and MAP kinase activity.
|
10508918 |
1999 |
|
Burkitt Lymphoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Akata and Mutu cell lines are derived from Burkitt's lymphoma (BL) and retain the in vivo phenotype of Epstein-Barr virus (EBV) expression that is characterized by expression of EBV-determined nuclear antigen 1 (EBNA1), EBV-encoded RNAs (EBERs) and transcripts from the BAM:HI A region (BARF0).
|
11118209 |
2000 |
|
Adult Burkitt Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Akata and Mutu cell lines are derived from Burkitt's lymphoma (BL) and retain the in vivo phenotype of Epstein-Barr virus (EBV) expression that is characterized by expression of EBV-determined nuclear antigen 1 (EBNA1), EBV-encoded RNAs (EBERs) and transcripts from the BAM:HI A region (BARF0).
|
11118209 |
2000 |
|
Childhood Burkitt Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Akata and Mutu cell lines are derived from Burkitt's lymphoma (BL) and retain the in vivo phenotype of Epstein-Barr virus (EBV) expression that is characterized by expression of EBV-determined nuclear antigen 1 (EBNA1), EBV-encoded RNAs (EBERs) and transcripts from the BAM:HI A region (BARF0).
|
11118209 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the present study we quantified SSTR2 and SSTR5 mRNA expression and the GH-suppressive effects of somatostatin-14; octreotide; a SSTR2-preferential compound, BIM-23197; a SSTR5-preferential compound, BIM-23268; and a new SSTR2- and SSTR5-bispecific compound, BIM-23244, in GH-secreting tumors classified as either full responders to octreotide (n = 5) or partially sensitive to octreotide (n = 5).
|
11231991 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, a new chimeric molecule, BIM-23A387, which selectively binds to the SS subtype 2 receptor (sst(2); K(i) = 0.10 nM) and to the DA D2 receptor (D2DR; K(i) = 22.1 nM) was tested in cultures prepared from 11 human GH-secreting tumors for its ability to suppress GH and prolactin (PRL) secretion.
|
12466351 |
2002 |
|
Mammary Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.
|
14527951 |
2003 |
|
Glioblastoma
|
0.060 |
AlteredExpression
|
disease |
LHGDN |
Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells.
|
15030401 |
2004 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
LHGDN |
The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells.
|
14996839 |
2004 |
|
T-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
LHGDN |
The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells.
|
14996839 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The high-resolution array CGH technology allowed for the precise identification of genomic aberrations and identification of BIM as a novel candidate tumor suppressor gene in MCL.
|
15608680 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proteasome inhibitor Velcade (P-341, Bortezomib) restored BIM induction, abrogated H-ras-dependent paclitaxel resistance, and promoted BIM-dependent tumor regression, suggesting the potential benefits of combinatorial chemotherapy of Velcade and paclitaxel.
|
15766661 |
2005 |
|
Mantle cell lymphoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The high-resolution array CGH technology allowed for the precise identification of genomic aberrations and identification of BIM as a novel candidate tumor suppressor gene in MCL.
|
15608680 |
2005 |
|
Glioblastoma
|
0.060 |
AlteredExpression
|
disease |
LHGDN |
Increased expression of Mcl-1 is required for protection against serum starvation in phosphatase and tensin homologue on chromosome 10 null mouse embryonic fibroblasts, but repression of Bim is favored in human glioblastomas.
|
16051596 |
2005 |
|
Adenoma
|
0.040 |
Biomarker
|
group |
BEFREE |
BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion.
|
16216913 |
2005 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.
|
15608680 |
2005 |
|
Multiple Myeloma
|
0.020 |
Biomarker
|
disease |
LHGDN |
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.
|
16091744 |
2005 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here we demonstrate that the proapoptotic BH3-only protein BIM is a tumor suppressor in epithelial solid tumors and also is a determinant in paclitaxel sensitivity in vivo.
|
15766661 |
2005 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244).
|
16216913 |
2005 |
|
Epithelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
|
15766661 |
2005 |
|
Infection
|
0.010 |
Biomarker
|
group |
LHGDN |
Broad degradation of proapoptotic proteins with the conserved Bcl-2 homology domain 3 during infection with Chlamydia trachomatis.
|
15731037 |
2005 |